About Eric Grabowski, MD, SCD

Dr. Grabowski is a pediatric hematologist/oncologist with interests in clinical hemostasis and thrombosis (including hemophilia and congenial and acquired bleeding disorders), venous and arterial thrombosis in children and adolescents, eye tumors in children (retinoblastoma), and general pediatric hematology/oncology.  He has additional training in cardiovascular physiology, laboratory coagulation, and biomedical engineering (doctorate in engineering science:  biofluid mechanics and physiologic blood flow.  He is Director of the MGH Comprehensive Hemophilia Treatment Center, Co-Director of the Pediatric Stroke Services and Director of the Cardiovascular Thrombosis Laboratory.  His medical degree is from Mayo Medical School, while his doctorate is from Columbia University.  He has completed fellowships in cardiovascular physiology and biophysics at the Mayo Graduate School of Medicine, and in pediatric hematology/oncology at New York Presbyterian Weil Cornell Medical Center and Memorial-Sloan Kettering Cancer Center, New York, NY.    He is an Assoc. Prof. of Pediatrics at Harvard Medical School. 

He is the Founding President of the Thrombosis and Hemostasis Societies of North America (THSNA), and also Chair and/or member of several national and international Boards and Committees.  These include the Board of THSNA;  the Board of the National Blood Clot Alliance; Chair of the Mentored Research Program and Chair of the Scientific Review Committee of the Hemostasis and Thrombosis Society of North America; member of the Data Safety Monitoring Board of the NHLBI for clinical trials in hemostasis and thrombosis; member of the International Data Safety Monitoring Board for emicizumab (new bispecific antibody treatment for hemophiliacs with high-titer inhibitors to either factor VIII or factor IX); and member of the Scientific Advisory Boards for CSL Behring, Octapharma, and Emergent BioSolutions.

Clinical Interests:



Mass General for Children: Pediatric Hematology & Oncology
55 Fruit St.
Yawkey Center for Outpatient Care
Suite 8B
Boston, MA 02114
Phone: 617-726-2737

Medical Education

  • MD, Mayo Medical School
  • Residency, Mayo Medical School
  • Fellowship, Memorial Sloan Kettering Cancer Center

American Board Certifications

  • Pediatric Hematology-Oncology, American Board of Pediatrics
  • Pediatrics, American Board of Pediatrics

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


While Dr. Grabowski is a practicing pediatric hematologist/oncologist at MGHfC with interests in bleeding and clotting disorders, pediatric stroke, retinoblastoma, immune cytopenias, and general hematology/oncology, he also directs an active research program, both as the Director of the Cardiovascular Thrombosis Laboratory and as Director of the Comprehensive Hemophilia Treatment Center.  An important project is the study of the pathophysiology of the childhood epidemic hemolytic uremic syndrome, a devastating renal failure disorder that primarily affects children under age 5 and for which there is at present no specific therapy, only supportive care.  Dr. Grabowski and colleagues have found that blockade of the lectin pathway of complement and blockade of the tissue factor pathway of coagulation together may constitute a promising therapeutic approach.  Further mouse and human tissue culture studies are necessary but these may set the stage for a clinical trial in children in the near future.  Another project is the use of a microfluidics blood flow chamber and real-time epifluorescence digital video microscopy to improve the diagnostic accuracy of type 1 von Willebrand disease (vWD), the most common of all inherited bleeding disorders.  Underdiagnosis and overdiagnosis remain the greatest challenges today in the field of vWD.  The imaging and flow system is currently undergoing modifications to permit mass production.  A parallel study is exploring the role of vWD of the von Willebrand factor propeptide, a protein found in some but not all factor concentrates for the treatment of vWD.  A recently established Retinoblastoma Registry (80 patients cared for by Dr. Grabowski at MGH) provides a platform to study the outcomes of chemotherapy in children treated for high-risk forms of intraocular tumor.   

Dr. Grabowski cared for an additional 320 retinoblastoma patients at Weil-Cornell Medical Center


    1. Grabowski EF, Ingelfinger JR, Liu B, and Kushak RI. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium. Thromb. Res. 2013;131:521-528. Epub 2013 May1.
    2. Grabowski EF, Liu B, Gerace MR, Kushak RI, and Ingelfinger JR: Shiga toxin-1 decreases endothelial
      cell tissue factor pathway inhibitor not co-localized with tissue factor on the cell membrane. Thromb.
      Res. 2015; 135:1214-1217.
    3. Grabowski EF: Retinoblastoma. Published online in Clinical Practice Guidelines, C. Boney, ed., 2015.
    4. Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC, Kushak RI, Skjoedt MO, Grabowski EF, Taira Y, Stahl GL. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int. 2016;90(4):774-782.
    5. Grabowski EF. From tumor suppressor to thrombus resolver. Blood 2017;129(24):3144-3145.
    6. Kushak RI, Ozaki M, Rosales IA, Boyle DC, Colvin RB, Ingelfinger JR, Stahl GL, Grabowski EF. Both platelets and fibrin deposition are increased in the glomeruli of mice after treatment with Shiga toxin-2. Kidney Int. 2017;92:1556-1557.
    7. Grabowski EF, Van Cott EM, Bornikova L, and Boyle DC. Differentiation of Patients with Type 1 von Willebrand Disease (vWD) and with Symptomatic Low Normal von Willebrand Factor (vWF) from those with Asymptomatic Low vWF, Using a Very High Shear Rate, High Image Resolution Blood Flow Chamber. Blood 2017; 130:2338; and J. Thromb. Haemost., Submitted, April 2018.


Reviews: Comments and Ratings